OXA-244-Producing Escherichia coli Isolates, a Challenge for Clinical Microbiology Laboratories - Archive ouverte HAL Access content directly
Journal Articles Antimicrobial Agents and Chemotherapy Year : 2017

OXA-244-Producing Escherichia coli Isolates, a Challenge for Clinical Microbiology Laboratories

(1, 2, 3) , (1, 4, 2, 3) , (1, 4, 2, 3) , (4) , (4) , (1, 4, 2, 3) , (1, 4, 2, 3)
1
2
3
4

Abstract

OXA-244 is a single-point-mutant derivative of OXA-48 displaying reduced carbapenemase activity. Here, we report the microbiological features of seven OXA-244-producing Escherichia coli isolates. Only one isolate grew on ChromID Carba Smart medium (bioMérieux), but six of the seven isolates grew on ChromID extended-spectrum-β-lactamase (ESBL) medium (bioMérieux), as they coproduced an ESBL and/or a plasmid-encoded cephalosporinase. The production of a carbapenemase was detected in 57.1%, 71.4%, 71.4%, and 100% of the E. coli isolates using the Carba NP test, the Rapidec Carba NP test (bioMérieux), a matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) hydrolysis assay (Bruker), and the OXA-48 K-SeT assay (Coris BioConcept), respectively. Our results indicate that OXA-244-producing E. coli isolates are difficult to detect, which may lead to their silent spread.
Fichier principal
Vignette du fichier
Hoyos_et_al_2017.pdf (839.91 Ko) Télécharger le fichier

Dates and versions

pasteur-03107799 , version 1 (12-01-2021)

Licence

Attribution - NonCommercial - CC BY 4.0

Identifiers

Cite

Yannick Hoyos-Mallecot, Thierry Naas, Rémy Bonnin, Rafael Patino, Philippe Glaser, et al.. OXA-244-Producing Escherichia coli Isolates, a Challenge for Clinical Microbiology Laboratories. Antimicrobial Agents and Chemotherapy, 2017, 61 (9), ⟨10.1128/AAC.00818-17⟩. ⟨pasteur-03107799⟩
32 View
28 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More